Context The role of adjuvant chemotherapy remains poorly defined for the management of
muscle-invasive bladder cancer (MIBC). The last meta-analysis evaluating adjuvant …

Papillary and invasive cancers of the urinary bladder appear to evolve and progress through
distinct molecular pathways. Invasion in bladder cancer forebodes a graver prognosis, and …

Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic
muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of …

In Europe, an estimated 151 297 new cases of bladder cancer were diagnosed in 2012, with
an age-standardised incidence rate (per 100000 persons) of 17.7 for males and 3.5 for …

Introduction Retrospective studies suggest that p53 alteration is prognostic for recurrence in
patients with urothelial bladder cancer and predictive for benefit from combination …

Simple Summary Urothelial bladder cancer (BC) is one of the most fatal cancers, with a
dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant …

CONTEXT: We present a summary of the Second International Consultation on Bladder
Cancer recommendations on chemotherapy for the treatment of bladder cancer using an …

Schistosoma-associated bladder cancer was believed, for several decades, to be a
completely unique entity of disease, different from urothelial cancer. This was probably due …

Purpose To provide a comprehensive overview and update of the Joint Société
Internationale d'Urologie–International Consultation on Urological Diseases (SIU–ICUD) …

Importance Despite existing evidence of a benefit associated with cisplatin-based adjuvant
chemotherapy (AC) after radical cystectomy (RC) for chemotherapy-naive patients with …